Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 71.53

+2.4%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sds who wrote (2058)	7/5/1998 10:59:00 PM
From: Scott H. Davis	Read Replies (2) of 4676

SDS, as you are re-examining ISIP, we may need to re-examine the re-examination. There was a consensus that the CMV Ret. drug may have much less market potential than 1st expected due the the efficacy of the protease inhibitors. Another article in past week puts that assumption in further doubt. There are now reports of several cases of protease resistant HIV, thought to be linked to non-complience with the exacting dosing regimine of the PIs. Looks like trouble in PI land. One benefit of the administration mode of ISIS CMS Ret. is that a patient can't skip or forget pills. Scott

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next